Gastrointestinal Cancer | Specialty

Maintenance Therapy in Metastatic Colorectal Cancer

September 29th 2013

Case Study: Borderline Resectable mCRC

September 29th 2013

Predictive Value of RAS Mutations in mCRC

September 29th 2013

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

September 29th 2013

EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013

TRIBE Trial: First-Line Treatment of mCRC

September 29th 2013

Dr. Mitchell on Survival and Safety of the VELOUR Trial

September 23rd 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.

Merrimack's GI Cancer Agents Show Promise

September 20th 2013

Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.

Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

September 18th 2013

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

First Generic Version of Capecitabine Gains FDA Approval

September 16th 2013

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Dr. Mitchell on Colorectal Cancer Treatment Options

September 10th 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

FDA Approves Nab-Paclitaxel for Advanced Pancreatic Cancer

September 6th 2013

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

Ruxolitinib Plus Capecitabine Improves Survival in Pancreatic Cancer

August 21st 2013

Adding ruxolitinib to capecitabine significantly improved the survival rate of a subgroup of patients with recurrent or treatment-refractory pancreatic cancer compared with patients in the same population who received capecitabine alone.

Dr. Eckhardt on Angiogenesis Inhibition in Metastatic CRC

August 20th 2013

Gail Eckhardt, MD, from the University of Colorado Denver and Health Sciences Center, discusses the future role of aflibercept for patients with metastatic colorectal cancer.

New Phase III Trial

August 19th 2013

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Dr. Lenz Describes Excitement Over Advances in GI Cancer

August 16th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

RAS Mutation Status Key to Panitumumab Use in mCRC

July 30th 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

Dr. Venook on Using Frailty Index & Geriatric Assessments

July 17th 2013

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the importance of utilizing frailty index and geriatric assessments for patients with cancer.

Dr. Kaufman on the Importance of the Immunoscore

July 16th 2013

Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer.